AI Drug Discovery Faces Patent Law Hurdles

Biotech companies are increasingly leveraging generative artificial intelligence to accelerate drug discovery, with Insilico Medicine being a prominent example. Insilico Medicine utilized its AI platform to propose a novel drug candidate for pulmonary fibrosis, a condition characterized by the scarring of lung tissue. The company's press release highlighted the AI's role in "discovering" the molecule, underscoring the growing capability of AI to generate complex molecular designs that might elude human researchers. This advancement positions AI as a powerful tool in the quest for new medical treatments, potentially shortening the timeline from initial concept to viable therapeutic.

Despite the AI's significant contribution to the drug's design, the subsequent patent filing by Insilico Medicine omitted any mention of artificial intelligence. Instead, the patent application named five human individuals, including CEO Alex Zhavoronkov, as the "inventors" of the new chemical structure. This discrepancy highlights a critical challenge at the intersection of AI innovation and intellectual property law: current legal frameworks do not recognize AI as an inventor. The United States Patent and Trademark Office (USPTO) and subsequent court rulings have maintained that patent law requires human inventors.

A significant legal precedent was set by a case involving Ryan Abbott, a partner at the law firm Brown, Neri, Smith & Khan. Abbott initiated a test case on a pro bono basis, attempting to name an AI system called DABUS as the inventor of an improved food container. This container featured an intricate geometric surface designed for enhanced heat transfer and stackability. Abbott's argument centered on the AI's sole contribution to the design, suggesting that if no human conceived the invention, the AI should be recognized. This case raised profound philosophical questions about AI personhood and the nature of inventive thought.

However, in 2022, an appeals court in Washington, D.C., dismissed these "metaphysical matters" as irrelevant to the legal determination. The court's decision rested on the interpretation of U.S. statutes, which define an inventor as an "individual." The court concluded that the plain meaning of "individual" refers exclusively to human beings, thus excluding machines from being recognized as inventors. Sarah Korman, patent attorney and chief business and legal officer at Isomo, affirmed this legal stance, stating, "There needs to be a human inventor or there’s no invention and no patent." This ruling solidifies the requirement for human inventorship in patent law, regardless of the extent of AI involvement in the creative process. The implications for AI-driven innovation are substantial, as companies must navigate these legal constraints to protect their AI-generated intellectual property.